Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
PT-141 (Bremelanotide) is FDA-approved as Vyleesi (June 2019) for hypoactive sexual desire disorder in premenopausal women, at a fixed 1.75mg subcutaneous dose. It activates melanocortin receptors (primarily MC3R/MC4R) in the brain, driving sexual desire centrally, unlike PDE5 inhibitors (Viagra/Cialis), which act peripherally on penile blood flow. It has no effect on skeletal muscle, testosterone, or the HPTA, and no performance-enhancing relevance whatsoever. FDA trial data show a modest but statistically significant improvement in desire scores over placebo, with no significant difference on the "satisfying sexual events" secondary endpoint. Rated 1 (basically natty): a libido/sexual-desire therapeutic does not raise muscle, strength, body composition, or endogenous anabolic hormones by any path, so it does not move the physique/performance ceiling at all.
Overview
A melanocortin agonist used for sexual dysfunction. FDA-approved (as Vyleesi) for hypoactive sexual desire disorder in premenopausal women; also used off-label by some men for sexual dysfunction, though it carries no FDA approval or official dosing guidance for that use.
Important Warnings
- •Do not use more than once in 24 hours
- •Maximum 8 doses per month recommended (FDA label)
- •Can cause significant nausea (~40% of patients). The main dose-limiting side effect
- •Causes a transient blood-pressure rise (and modest heart-rate dip) after each dose, avoid in uncontrolled hypertension or cardiovascular disease
- •Repeated dosing can cause focal skin/gum hyperpigmentation (~1% of patients) that is not confirmed to fully resolve after stopping
- •May significantly reduce absorption of oral naltrexone-containing products. Avoid combining, per FDA labeling
- •Not FDA-approved for men or postmenopausal women; off-label use has no official dosing guidance and is typically sourced via compounding pharmacies/telehealth with unverified dosing accuracy
Purpose & Use Cases
Sexual Desire
Increases libido and sexual desire in both men and women.
Erectile Function
May support erectile function via central-nervous-system action, and showed an enhanced response when combined with low-dose sildenafil in a small trial, though standalone development for male erectile dysfunction was discontinued after the FDA raised blood-pressure concerns over the intranasal formulation.
Female Sexual Dysfunction
FDA-approved for hypoactive sexual desire disorder in premenopausal women.
Benefits
- Increased sexual desire
- Works on desire, not just function
- Clinically validated (FDA-approved) efficacy in women; also used off-label by men
- FDA-approved
- May complement PDE5 inhibitors via a different (central) mechanism
Good to Know
It works in the brain, not the blood vessels
PT-141 is a melanocortin agonist (MC3R/MC4R in the hypothalamus) that raises sexual DESIRE centrally. That is fundamentally different from Viagra/Cialis, which are PDE5 inhibitors acting on penile blood flow. Because it drives desire rather than plumbing, it targets libido itself rather than just the mechanics of an erection, and a small trial found an enhanced response when combined with low-dose sildenafil.
Nausea is the dose-limiter
Nausea (~40% of trial patients) is the clear dose-limiter. It is typically worst with the first dose and eases with continued use. PT-141 also causes transient facial flushing (~20%) and a modest blood-pressure rise with a slight heart-rate dip after every dose. Avoid it with uncontrolled hypertension or cardiovascular disease.
It is Melanotan II's active metabolite
Bremelanotide is the active metabolite of Melanotan II, which is why MT-II also boosts libido. The trade-off: PT-141 lacks the strong MC1R tanning drive of MT-II, but with repeated dosing it can still cause focal skin/gum darkening (~1% of patients, more likely with darker skin, not always confirmed reversible after stopping) because it does touch MC1R.
FDA-approved for women, used off-label in men
Approved as Vyleesi (fixed 1.75mg SC dose) for premenopausal women with hypoactive sexual desire disorder, explicitly not indicated for postmenopausal women or men. Male use is entirely off-label with no official dosing; clinics extrapolate from the female dose but should respect the same nausea/BP cautions and dosing-frequency limits.
Dosage Guidelines
| Experience Level | Dosage Range |
|---|---|
| Beginner | 0.5 – 1 mg/day |
| Intermediate | 1.75 – 2 mg/day |
| Advanced | 2 – 4 mg/day |
The FDA-approved dose (Vyleesi, women) is a fixed 1.75mg SC per dose. There is no titration/loading phase. The label recommends discontinuing after 8 weeks if no symptom improvement is reported; responders commonly continue as-needed indefinitely rather than following a fixed "cycle." Off-label male dosing has no official guidance and is community/clinic-derived: a low 0.5-1mg test dose to gauge nausea sensitivity, then 1.75-2mg as a working dose, with some heavier protocols reported up to ~4mg. Treat anything above the approved 1.75mg as unverified/community-sourced, not clinically established. More frequent dosing raises nausea and blood-pressure-spike risk per the FDA label.
Side Effects
Nausea
very commonThe most common side effect, reported in roughly 40% of patients in FDA trials; vomiting occurred in about 5%. Typically most intense with the first dose and improves with subsequent doses, about 13% of trial patients used an antiemetic.
Nausea generally lessens after the first couple of doses; an antiemetic can help if needed. Off-label users often start at a lower dose to gauge sensitivity.
Facial Flushing
commonRedness and warmth in the face/chest, reported in about 20% of patients.
Normal and transient; usually resolves within a few hours.
Blood Pressure / Heart Rate Changes
very commonPer the FDA label, a transient blood-pressure rise (average +6 mmHg systolic / +3 mmHg diastolic) with a modest heart-rate decrease occurs after each dose, peaking 2-4 hours post-injection and typically resolving within about 12 hours. More frequent dosing raises the risk of a more pronounced effect.
Contraindicated with uncontrolled hypertension or known cardiovascular disease. Do not exceed the labeled dosing frequency.
Injection Site Reactions
commonPain, redness, swelling, itching or bruising at the injection site, reported in roughly 13% of patients.
Rotate injection sites between the abdomen and thigh; usually mild and self-limited.
Focal Hyperpigmentation
rareLocalized skin darkening (including the face, gums and breasts) reported in about 1% of patients receiving repeated dosing; more likely in patients with darker skin. Per the FDA label, resolution after stopping was not confirmed in all cases.
More likely with frequent, prolonged use. Discuss any new or spreading pigmentation with a prescriber and consider limiting dosing frequency.
General Mitigation Strategies
Do not exceed one dose in 24 hours or 8 doses per month (FDA labeling), more frequent dosing raises the risk of pronounced blood-pressure effects. Nausea is usually worst with the first dose and improves with continued use; an antiemetic can help if needed. Avoid use with uncontrolled high blood pressure or known cardiovascular disease, and monitor for any new/spreading skin darkening with repeated use.
Post Cycle Therapy (PCT)
Not hormonal in the traditional sense. No PCT required.
How It Works
PT-141 activates melanocortin receptors (MC3R and MC4R) in the brain, which are involved in sexual arousal and desire. Unlike PDE5 inhibitors (Viagra), it works centrally on desire rather than just blood flow.
Fundamentals
Reference on the practices relevant to PT-141: how they are done and where they go wrong. Not a recommendation to use it.
Legal Status
FDA-approved as Vyleesi (June 2019); not a controlled substance. Explicitly not indicated for postmenopausal women or men. Off-label male use is unapproved and typically sourced via compounding pharmacies/telehealth clinics.
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
PT-141 (Bremelanotide/Vyleesi) is not named on the WADA Prohibited List and is an FDA-approved medication with no established performance-enhancing effect on muscle, strength, or the HPTA, analogous to other permitted sexual-health medications like PDE5 inhibitors.